HONOLULU — In patients with Barrett's esophagus, low-grade dysplasia carries a substantial risk for progression to esophageal adenocarcinoma, investigators report. The risk for progression in patients ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new study data demonstrating ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that the use ...
Bethesda, MD (May 17, 2024) — The American Gastroenterological Association’s (AGA) new evidence-based Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related ...
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates ...
Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the eighth most ...
Please provide your email address to receive an email when new articles are posted on . Pooled annual progression rates were 0.02% and 0.01% among men and women, respectively, with Barrett’s esophagus ...
Craig Griffeth, 74, has always worried about cancer. “My aunts and uncles, almost all of them on both sides, died of cancer,” he said. “So, I figured that one day I’m going to get cancer, and I’ll ...
Strong recommendation for EET in patients with BE high-grade dysplasia based on available evidence. HealthDay News — In a clinical practice guideline issued by the American Gastroenterological ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback